Figure 1.
![Figure 1. Time on study. Swim lane plot of time on study for the 25 patients who achieved an objective response (≥ PR). Y-axis indicates refractoriness (naive [Naï], relapsed [Rel], or refractory [Ref]) of the patient’s myeloma to a PI (bortezomib, carfilzomib, or ixazomib). Arrows indicate patient is still on study. × indicates that patient is off study due to PD, adverse event (WC-AE), death, travel issues, or decreased quality of life (WC-QoL).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/132/24/10.1182_blood-2018-06-858852/6/blood858852f1.png?Expires=1735484756&Signature=15xIhBUeBvm7XUY823bG3Z19pTrjURfvu-MZc5ktLoyifuv8ot3vDT4R80y2q2xWZ7LBLpD9eplQiwIeZd-vf~9elC-a1r4mOnNp7KvykIbi6fUwGQ4iFD7Uoqjl3A4qWNrWQRkHNu~HRbJevFmReYCHrw5lwvHFC0wdCugWVn~z8zm332cLfHuIKjpG9Ixa2DQ6wQKRq6NWygGmByeMJxSsiSXw7BQj8RAArc7OHqeowgKGzzL3kPvqTd7hRz0LitsBHazXD98zDFqaqDNaDLZLLOhEc6CnLGcHZqbn~1IDA8KyxAeLuRHQJC1qwhp7AxbWA3BOtZB9U86JiERaXw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Time on study. Swim lane plot of time on study for the 25 patients who achieved an objective response (≥ PR). Y-axis indicates refractoriness (naive [Naï], relapsed [Rel], or refractory [Ref]) of the patient’s myeloma to a PI (bortezomib, carfilzomib, or ixazomib). Arrows indicate patient is still on study. × indicates that patient is off study due to PD, adverse event (WC-AE), death, travel issues, or decreased quality of life (WC-QoL).